Metropolis Healthcare Reports Fiscal Year 2026 Results

Metropolis Healthcare has announced its audited financial results for the fiscal year ended March 31, 2026. The company posted consolidated revenue of ₹1645.85 crore, with a profit after tax (PAT) of ₹144.97 crore. On a standalone basis, revenue stood at ₹1381.80 crore and profit after tax was ₹124.34 crore.

Dividend and Auditor Appointments

The company's Board of Directors, in a meeting held on May 13, 2026, also approved a second interim dividend of ₹1 per equity share for the fiscal year 2025-26. The record date for this dividend has been set as May 19, 2026.

In a significant governance update, the Board appointed Deloitte Haskins & Sells Chartered Accountants LLP as the new statutory auditors. This appointment is for a five-year term, commencing after the company's 26th Annual General Meeting (AGM).

Additionally, Dr. Nilesh Shah, President - Internal Assurance, will transition from his current role to an advisory capacity, effective May 14, 2026.

Financial Performance and Shareholder Returns

The reported results show Metropolis Healthcare's financial performance for FY2025-26. The previous fiscal year, FY2024-25, saw a consolidated profit after tax of approximately ₹135.3 crore, indicating a year-on-year growth in profitability. The declaration of the interim dividend is a direct return of earnings to shareholders, a move consistent with the company's history of rewarding its investors.

Governance and Oversight

The appointment of Deloitte Haskins & Sells as the new statutory auditor signifies a fresh chapter in the company's financial oversight. This change in auditors is expected to bring a new perspective to compliance and financial reporting scrutiny for the next five years. Dr. Shah's shift to an advisory role suggests a planned approach to leadership continuity, ensuring strategic guidance while stepping back from day-to-day operations.

Market Position and Competitive Landscape

Metropolis Healthcare is a prominent player in India's diagnostic services sector, recognized for its extensive network of laboratories and broad range of services. While its FY26 consolidated PAT of ₹144.97 crore is less than that of competitors like Dr. Lal PathLabs (approximately ₹350 crore) and Vijaya Diagnostic Centre (approximately ₹250 crore), the company continues to compete effectively through its network reach and service diversity.

Upcoming Actions and Investor Focus

Investors will be watching for shareholder approval of Deloitte Haskins & Sells as the new statutory auditors at the upcoming 26th AGM. The company is also expected to confirm the dividend payment within 30 days of declaration. Key areas to monitor will include the operational adjustments following Dr. Shah's transition to his advisory role and Metropolis Healthcare's performance in upcoming quarters relative to its peers in the dynamic diagnostic market.

Risks to Monitor

No specific governance or regulatory risks related to this announcement were highlighted in the provided company filing or in initial market research.